Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$42.78 -0.9%	$37.30	$21.72 ▼ $45.48	$8.12B	1.11	2.49 million shs	2.78 million shs
BEAM Beam Therapeutics	$17.53 +3.1%	$17.66	$13.53 ▼ $35.25	$1.76B	2.09	1.49 million shs	1.58 million shs
LNTH Lantheus	$79.42 -3.0%	$84.34	$73.11 ▼ $126.89	$5.50B	0.11	1.02 million shs	931,757 shs
ROIV Roivant Sciences	$10.94 -2.9%	$11.13	$8.73 ▼ $13.06	$7.44B	1.17	5.68 million shs	14.00 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-3.74%	+2.40%	+25.56%	+30.77%	+70.47%
BEAM Beam Therapeutics	+1.25%	+1.80%	+8.07%	-3.57%	-27.40%
LNTH Lantheus	+0.45%	+1.30%	+8.41%	-16.41%	+1.96%
ROIV Roivant Sciences	-1.05%	-2.00%	+2.64%	+14.42%	+6.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.7079 of 5 stars	4.5	2.0	3.9	2.5	3.3	0.6
BEAM Beam Therapeutics	2.3453 of 5 stars	3.5	1.0	0.0	2.2	2.5	0.6
LNTH Lantheus	4.4323 of 5 stars	3.5	1.0	4.2	2.1	2.5	1.9
ROIV Roivant Sciences	2.0961 of 5 stars	3.5	1.0	0.0	2.7	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.93	Moderate Buy	$58.85	37.56% Upside
BEAM Beam Therapeutics	3.00	Buy	$48.75	178.09% Upside
LNTH Lantheus	3.00	Buy	$130.50	64.32% Upside
ROIV Roivant Sciences	3.00	Buy	$17.50	59.96% Upside

Current Analyst Ratings Breakdown

Latest BEAM, ROIV, LNTH, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	BBIO BridgeBio Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$67.00 ➝ $76.00
6/25/2025	BBIO BridgeBio Pharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $54.00
6/23/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $109.00
6/18/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
6/17/2025	BBIO BridgeBio Pharma	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$49.00
6/9/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$53.00 ➝ $56.00
5/28/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/8/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $117.00
5/7/2025	BEAM Beam Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $55.00
5/7/2025	BEAM Beam Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $70.00
5/7/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $25.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$221.90M	36.61	N/A	N/A	($7.71) per share	-5.55
BEAM Beam Therapeutics	$63.52M	27.75	N/A	N/A	$8.86 per share	1.98
LNTH Lantheus	$1.53B	3.58	$6.91 per share	11.49	$15.65 per share	5.07
ROIV Roivant Sciences	$29.05M	256.01	N/A	N/A	$7.45 per share	1.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.52	22.56	12.59	N/A	16.55%	36.99%	20.55%	7/30/2025 (Estimated)
ROIV Roivant Sciences	-$171.98M	-$0.25	N/A	N/A	N/A	-225.71%	-14.76%	-13.69%	8/6/2025 (Estimated)

Latest BEAM, ROIV, LNTH, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.57	4.54
BEAM Beam Therapeutics	N/A	8.81	8.81
LNTH Lantheus	0.49	5.74	5.46
ROIV Roivant Sciences	N/A	33.47	33.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
BEAM Beam Therapeutics	99.68%
LNTH Lantheus	99.06%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
BEAM Beam Therapeutics	3.50%
LNTH Lantheus	2.00%
ROIV Roivant Sciences	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
LNTH Lantheus	700	69.19 million	67.80 million	Optionable
ROIV Roivant Sciences	860	679.81 million	626.10 million	Optionable

BEAM, ROIV, LNTH, and BBIO Headlines

Recent News About These Companies

'Just the beginning': Vivek Ramaswamy breaks record in raising fund for Guv election campaign, $8.5 million in five months

June 28 at 2:39 AM | msn.com

Roivant Sciences’ president Venker sells $1.15 million in shares

June 26, 2025 | investing.com

Investors Buy Large Volume of Roivant Sciences Call Options (NASDAQ:ROIV)

June 26, 2025 | marketbeat.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells $6,612,500.22 in Stock

June 26, 2025 | americanbankingnews.com

Vivek Ramaswamy Sells 565,266 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

June 26, 2025 | americanbankingnews.com

Penn Davis Mcfarland Inc. Has $17.23 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 25, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,145,000.00 in Stock

June 25, 2025 | insidertrades.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 100,000 Shares

June 24, 2025 | marketbeat.com

Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat

June 24, 2025 | msn.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells 565,266 Shares of Stock

June 24, 2025 | insidertrades.com

Roivant Sciences (ROIV) : Ramaswamy vend des actions pour 13 millions

June 23, 2025 | fr.investing.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells $6,472,295.70 in Stock

June 23, 2025 | marketbeat.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells 577,007 Shares of Stock

June 23, 2025 | marketbeat.com

Assenagon Asset Management S.A. Takes $570,000 Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 20, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Shares Up 5.4% - What's Next?

June 18, 2025 | marketbeat.com

HC Wainwright Reiterates Buy Rating for Roivant Sciences (NASDAQ:ROIV)

June 18, 2025 | marketbeat.com

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

June 16, 2025 | globenewswire.com

Roivant Sciences à la conférence Goldman Sachs : focus sur l’exécution stratégique

June 10, 2025 | fr.investing.com

Roivant Sciences Ltd. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 04:00 PM

June 10, 2025 | zonebourse.comZ

GAMMA Investing LLC Has $6.49 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 10, 2025 | marketbeat.com

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

June 9, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAM, ROIV, LNTH, and BBIO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$42.78 -0.40 (-0.93%)

Closing price 04:00 PM Eastern

Extended Trading

$42.96 +0.19 (+0.43%)

As of 07:07 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Beam Therapeutics NASDAQ:BEAM

$17.53 +0.52 (+3.06%)

Closing price 04:00 PM Eastern

Extended Trading

$17.44 -0.09 (-0.48%)

As of 07:26 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Lantheus NASDAQ:LNTH

$79.42 -2.44 (-2.98%)

Closing price 04:00 PM Eastern

Extended Trading

$80.65 +1.23 (+1.55%)

As of 06:58 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$10.94 -0.33 (-2.93%)

Closing price 04:00 PM Eastern

Extended Trading

$10.86 -0.07 (-0.69%)

As of 06:59 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time